News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Symphogen A/S to Report New Data on Anti-EGFR Monoclonal Antibody Mixture at American Society of Clinical Oncology


5/30/2013 7:03:18 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today an oral presentation and a poster at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. Both cover the results of proof-of-concept studies of SYM004, an anti-EGFR monoclonal antibody (mAb) mixture. Symphogen entered the antibody mixture into the clinic in 2010, and subsequently partnered with Merck KGaA, Darmstadt, Germany, in September 2012.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES